Literature DB >> 31730886

Synthetic cannabinoids JWH-018, JWH-122, UR-144 and the phytocannabinoid THC activate apoptosis in placental cells.

Marta Almada1, Patrícia Alves1, Bruno M Fonseca1, Félix Carvalho2, Cláudio R Queirós3, Helena Gaspar4, Cristina Amaral1, Natércia A Teixeira1, Georgina Correia-da-Silva5.   

Abstract

The increasing use of synthetic cannabinoids (SCBs) in recreational settings is becoming a new paradigm of drug abuse. Although SCBs effects mimic those of the Cannabis sativa plant, these drugs are frequently more potent and hazardous. It is known that endocannabinoid signalling plays a crucial role in diverse reproductive events such as placental development. Moreover, the negative impact of the phytocannabinoid Δ9-tetrahydrocannabinol (THC) in pregnancy outcome, leading to prematurity, intrauterine growth restriction and low birth weight is well recognized, which makes women of childbearing age a sensitive group to developmental adverse effects of cannabinoids. Placental trophoblast turnover relies on regulated processes of proliferation and apoptosis for normal placental development. Here, we explored the impact of the SCBs JWH-018, JWH-122 and UR-144 and of the phytocannabinoid THC in BeWo cell line, a human placental cytotrophoblast cell model. All the cannabinoids caused a significant decrease in cell viability without LDH release, though this effect was only detected for the highest concentrations of THC. Moreover, a cell cycle arrest at the G2/M phase was also observed. JWH-018 and JWH-122 increased reactive oxygen species (ROS) production and THC, UR-144 and JWH-122 caused loss of mitochondrial membrane potential. All the compounds were able to induce caspase-9 activation. The involvement of apoptotic pathways was further confirmed through the significant increase in caspase -3/-7 activities. For UR-144, this effect was reversed by the CB1 antagonist AM281, for JWH-018 and THC this effect was mediated by both cannabinoid receptors CB1 and CB2 while for JWH-122 it was cannabinoid receptor-independent. This work demonstrates that THC and SCBs are able to induce apoptotic cell death. Although they may act through different mechanisms and potencies, the studied cannabinoids have the potential to disrupt gestational fundamental events.
Copyright © 2019 The Authors. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Apoptosis; BeWo; Cells; Cytotrophoblasts; JWH-018; JWH-122; Placenta; Synthetic cannabinoids; UR-144; Δ(9)-Tetrahydrocannabinol

Year:  2019        PMID: 31730886     DOI: 10.1016/j.toxlet.2019.11.004

Source DB:  PubMed          Journal:  Toxicol Lett        ISSN: 0378-4274            Impact factor:   4.372


  5 in total

Review 1.  The Role of Cannabinoids in CNS Development: Focus on Proliferation and Cell Death.

Authors:  Eduardo Cosendey Bockmann; Rafael Brito; Lucianne Fragel Madeira; Luzia da Silva Sampaio; Ricardo Augusto de Melo Reis; Guilherme Rapozeiro França; Karin da Costa Calaza
Journal:  Cell Mol Neurobiol       Date:  2022-08-04       Impact factor: 4.231

2.  Delta-9-tetrahydrocannabinol inhibits invasion of HTR8/SVneo human extravillous trophoblast cells and negatively impacts mitochondrial function.

Authors:  O'Llenecia S Walker; Harmeet Gurm; Reeti Sharma; Navkiran Verma; Linda L May; Sandeep Raha
Journal:  Sci Rep       Date:  2021-02-17       Impact factor: 4.379

3.  Cannabidiol disrupts apoptosis, autophagy and invasion processes of placental trophoblasts.

Authors:  Patrícia Alves; Cristina Amaral; Natércia Teixeira; Georgina Correia-da-Silva
Journal:  Arch Toxicol       Date:  2021-07-24       Impact factor: 5.153

Review 4.  Pros and Cons of the Cannabinoid System in Cancer: Focus on Hematological Malignancies.

Authors:  Natasha Irrera; Alessandra Bitto; Emanuela Sant'Antonio; Rita Lauro; Caterina Musolino; Alessandro Allegra
Journal:  Molecules       Date:  2021-06-24       Impact factor: 4.411

Review 5.  Novel Psychoactive Substances: The Razor's Edge between Therapeutical Potential and Psychoactive Recreational Misuse.

Authors:  Beatriz Correia; Joana Fernandes; Maria João Botica; Carla Ferreira; Alexandre Quintas
Journal:  Medicines (Basel)       Date:  2022-03-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.